CGM has Similar Predictive Performance to OGTT for Monitoring Early-Stage Type 1 Diabetes

Clicks: 77
ID: 331434
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #22 of 448 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 448 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objective Compare continuous glucose monitoring (CGM) and other metabolic markers in progression to stage 3 type 1 diabetes (T1D) in early-stage T1D and evaluate CGM time above 140 mg/dl (TA140) across different stages. Methods In a combined dataset from three prospective studies, 152 early-stage T1D individuals had baseline CGM, oral glucose tolerance test (OGTT) and HbA1c with 54 (36%) progressing to stage 3. ROC curves were generated to compare the areas under the curve (AUC) for stage 3 prediction. Risk of progression was estimated by Accelerated Failure Time (AFT) and Kaplan–Meier analyses. Results TA140 > 10% and 2 hr glucose>140 mg/dl had the exact same specificity (83%), negative predictive value (88%) and sensitivity (55%) for stage 3 prediction at 2 years. In univariable AFT, the HRs for stage 3 at 5 years were significant for all CGM metrics tested (all p<=0.008), while significant OGTT metrics included 2hr-glucose, AUC_glucose, AUC_C-peptide and peak_C-peptide (all p<=0.021). In multivariable AFT, younger age, male sex, HbA1c>=5.7%, TA140 > 15% and 2-hr glucose>140 mg/dl were strong predictors of accelerated progression to stage 3. Cumulative incidence curves for stage 3 were similar for TA140 > 15%, HbA1c>=5.7% and 2hr-glucose>140 mg/dl. Among 406 longitudinal CGMs, participants at stage 3 had higher median TA140 (17.2%, IQR 7.9-33.2) compared to stage 2 (8.6%, IQR 3.8-15.2) and stage 1 (3.2%, IQR 1.3-7.7) (all pairwise p<=0.024). Conclusions In this largest dataset of individuals at early-stage T1D, we define CGM-derived TA140 criteria for the various stages. Furthermore, we show that TA140 has similar performance to a 2-hour OGTT value for predicting stage 3.
Reference Key
openalex_W7220702573 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Andrea K. Steck, Fran Dong, Laura L. Pyle, Tim Vigers, Darrell M. Wilson, Kimber M. Simmons, Marian Rewers, Brigitte I. Frohnert
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag394
URL
https://doi.org/10.1210/clinem/dgag394
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.